Non-Small Cell Lung Cancer (NSCLC) - Metastatic

IRB# 19009
A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with NSCLC

IRB# 19330
A Phase 3, randomized, double-blind trial of pembrolizumab with or without lenvatinib in participants with treatment-naive, metastatic NSCLC whose tumors have a tumor proportion score greater than or equal to 1%

IRB# 19350
A Phase 1/2 study of the safety, pharmacokinetics and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC

IRB# 19351
A Phase 3, randomized, double-blind trial of pembrolizumab with or without lenvatinib in participants with treatment-naive, metastatic NSCLC whose tumors have a tumor proportion score greater than or equal to 1%

IRB# 19009
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC

IRB# 19505
A Phase 3, randomized, double-blind trial of pembrolizumab with or without lenvatinib as First-line Intervention in Participants with Metastatic Nonsquamous NSCLC

IRB# 19505
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC

IRB# 19009
A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with NSCLC

IRB# 11462
A Randomized, Open-label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib plus paclitaxel as Second-Line Treatment for Stage IIIB or IV NSCLC

IRB# 19566
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NSCLC (LUNG-MAP Sub-Study)

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php